Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Prothena Corp (PRTA)

Prothena Corp (PRTA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 388,285
  • Shares Outstanding, K 39,865
  • Annual Sales, $ 960 K
  • Annual Income, $ -155,650 K
  • 60-Month Beta 2.36
  • Price/Sales 414.93
  • Price/Cash Flow N/A
  • Price/Book 1.27

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.56
  • Number of Estimates 2
  • High Estimate -0.55
  • Low Estimate -0.56
  • Prior Year -0.98
  • Growth Rate Est. (year over year) +42.86%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.67 +9.46%
on 06/07/19
10.34 -8.22%
on 06/20/19
unch (unch)
since 05/24/19
3-Month
8.67 +9.46%
on 06/07/19
12.54 -24.32%
on 04/05/19
-2.81 (-22.85%)
since 03/22/19
52-Week
8.63 +9.97%
on 12/24/18
15.91 -40.35%
on 09/04/18
-6.18 (-39.44%)
since 06/22/18

Most Recent Stories

More News
Prothena (PRTA) Down 14.1% Since Last Earnings Report: Can It Rebound?

Prothena (PRTA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

PRTA : 9.52 (-2.26%)
Prothena to Participate in the Jefferies Healthcare Conference

Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company, today announced that members of its senior management team will present and participate in the Jefferies Healthcare Conference...

PRTA : 9.52 (-2.26%)
Shares of Ptc Therapeutics Rank the Highest in Terms of Relative Performance in the Biotechnology Industry (PTCT , AMAG , PRTA , GBT , MRTX)

We looked at the Biotechnology industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look at...

PTCT : 42.36 (-2.96%)
PRTA : 9.52 (-2.26%)
AMAG : 8.49 (-5.35%)
MRTX : 101.53 (+0.09%)
Prothena's (PRTA) Q1 Earnings Beat Estimates, Revenues Miss

Prothena's (PRTA) Q1 loss was narrower than expected, while revenues missed expectations.

CELG : 93.52 (-5.45%)
PRTA : 9.52 (-2.26%)
RHHBY : 35.3900 (-0.59%)
BMY : 45.67 (-7.44%)
Prothena (PRTA) Reports Q1 Loss, Misses Revenue Estimates

Prothena (PRTA) delivered earnings and revenue surprises of 13.33% and -7.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

PRTA : 9.52 (-2.26%)
Prothena Reports First Quarter 2019 Financial Results and Provides R&D Update

-- Net cash used in operating and investing activities was $17.6 million in the first quarter; quarter-end cash and restricted cash position of $414.2 million provides funding to advance neuroscience pipeline...

PRTA : 9.52 (-2.26%)
Prothena Reports First Quarter 2019 Financial Results and Provides R&D Update

- Net cash used in operating and investing activities was $17.6 million in the first quarter; quarter-end cash and restricted cash position of $414.2 million provides funding to advance neuroscience pipeline...

PRTA : 9.52 (-2.26%)
Prothena to Report First Quarter 2019 Financial Results on May 7

Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company, will announce financial results for the first quarter of 2019 on May 7, 2019 after the close of the U.S. financial markets....

PRTA : 9.52 (-2.26%)
Prothena Reports Results from the Phase 3 VITAL Amyloidosis Study of NEOD001 (birtamimab) in AL Amyloidosis

-- Results from final analysis of the composite primary endpoint were consistent with the futility analysis reported in April 2018

PRTA : 9.52 (-2.26%)
Analysis: Positioning to Benefit within Cleveland-Cliffs, Wix, F5 Networks, Prothena Corporation plc, McCormick & Company, and NII -- Research Highlights Growth, Revenue, and Consolidated Results

In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Cleveland-Cliffs Inc. (NYSE:CLF),...

NIHD : 1.83 (-2.66%)
MKC : 154.31 (-0.06%)
WIX : 144.39 (-2.52%)
PRTA : 9.52 (-2.26%)
CLF : 9.85 (-2.09%)
FFIV : 143.15 (-0.40%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade PRTA with:

Business Summary

Prothena Corporation plc is a biotechnology company focused on the discovery and development of therapeutic monoclonal antibodies for disease-causing proteins. The Company is developing the following programs: NEOD001 for Amyloidosis, NEOD002 for Parkinson's disease, MCAM for Inflammatory disease and...

See More

Key Turning Points

2nd Resistance Point 10.30
1st Resistance Point 10.02
Last Price 9.52
1st Support Level 9.54
2nd Support Level 9.34

See More

52-Week High 15.91
Fibonacci 61.8% 13.13
Fibonacci 50% 12.27
Fibonacci 38.2% 11.41
Last Price 9.52
52-Week Low 8.63

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar